Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Drug Combinations Against Triple Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who will be in class one to six by the time of study~* Aged 5-18 years and found infected with either SCH, any STH or LF for treatment groups 1,2 or 3 or infected with both SCH and LF for treatment group 4 and infected with all the three for treatment group 5~* Who are willing and consent and whose parents will consent, will be included in the study.~Exclusion Criteria:~* Those with acute and chronic diseases other than the targeted infections and those with a history of any serious adverse drug reactions will not be included in the study.~* Children with total bilirubin \> 50µmol/L and ALAT (Alanine transferase) \> 70IU/L will not qualify for recruitment.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): albendazole + ivermectin + praziquantel
- 2 (Type: PLACEBO_COMPARATOR): albendazole + ivermectin + (1 week later) praziquantel

Based on this trial design, predict the completion outcome and termination type (if applicable).